Serum Metabolic Profiling of Late-Pregnant Women With Antenatal Depressive Symptoms

Qiang Mao 3†, Tian Tian 4†, Jing Chen 2†, Xunyi Guo 5, Xueli Zhang 6 and Tao Zou 1,2*

1 Shanghai Key Laboratory of Forensic Medicine (Academy of Forensic Science), Shanghai, China, 2 Department of Psychiatry, The Affiliated Hospital of Guizhou Medical University, Guiyang, China, 3 Department of Pharmacology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China, 4 Department of Neurology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China, 5 Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China, 6 Department of Psychiatry, Linyi Mental Health Center, Linyi, China

Background: Antenatal depression (AD) is a major public health issue worldwide and lacks objective laboratory-based tests to support its diagnosis. Recently, small metabolic molecules have been found to play a vital role in interpreting the pathogenesis of AD. Thus, non-target metabolomics was conducted in serum.

Methods: Liquid chromatography—tandem mass spectrometry—based metabolomics platforms were used to conduct serum metabolic profiling of AD and non-antenatal depression (NAD). Orthogonal partial least squares discriminant analysis, the non-parametric Mann–Whitney U test, and Benjamini–Hochberg correction were used to identify the differential metabolites between AD and NAD groups; Spearman's correlation between the key differential metabolites and Edinburgh Postnatal Depression Scale (EPDS) and the stepwise logistic regression analysis was used to identify potential biomarkers.

Results: In total, 79 significant differential metabolites between AD and NAD were identified. These metabolites mainly influence amino acid metabolism and glycerophospholipid metabolism. Then, PC (16:0/16:0) and betaine were significantly positively correlated with EPDS. The simplified biomarker panel consisting of these three metabolites [betaine, PC (16:0/16:0) and succinic acid] has excellent diagnostic performance (95% confidence interval = 0.911–1.000, specificity = 95%, sensitivity = 85%) in discriminating AD and NAD.

Conclusion: The results suggested that betaine, PC (16:0/16:0), and succinic acid were potential biomarker panels, which significantly correlated with depression; and it could make for developing an objective method in future to diagnose AD.

Keywords: antenatal depression, metabolomics, edinburgh postnatal depression scale, biomarker, amino acid metabolism, glycerophospholipid metabolism
INTRODUCTION

Antenatal depression (AD), defined as depression during pregnancy up to the point of birth, is one of the most widespread psychiatric disorders and produces harmful effect on the mother and the infant’s health (1, 2). Systematic reviews determined that the prevalence of antenatal had a significant increasing trend in the last decade and varied in different countries and regions, such as 19.7% in mainland China, 50% in Nepal, and 30–40% in South Africa (3–5). Women with AD are more likely to develop several complications, including an increased risk of nausea, vomiting, miscarriage, and poor cognitive and fetal growth, which even develop into postpartum depression (6). For offspring, AD not only results in prematurity to the fetus or in low birth weight, but also has a steady adverse effect on their brain, behavior, immune function, and hypothalamic–pituitary–adrenal (HPA) function (3, 7, 8). Therefore, AD is a still major public health issue worldwide, and it is very important to find better measures to prevent and treat AD.

As it is well-known, depression disorder is greatly influenced by genetics and environmental factors, as well as their interactions (9, 10). AD is accompanied by physiological and psychological changes, which results in alteration of hormones, inflammatory cytokines, HPA axis (11–14). Christian et al. have reported that depressive symptoms of AD are associated with elevated serum pro-inflammatory cytokines [interleukin 6 (IL-6) and tumor necrosis factor α] among pregnant women (15). Similarly, higher cerebrospinal fluid IL-1β, IL-23, and IL–33 concentrations were significantly associated with increased odds of perinatal depression (16). However, there are still no empirical laboratory methods to diagnose antepartum depression. Currently, AD diagnosis heavily depends on clinical features and syndrome, identified by experienced psychiatrists (17). As a result, many patients could be misdiagnosed or never diagnosed for the high heterogeneity of depressive symptoms (17–19). Thus, an effective diagnostic method for AD would be of considerable clinical significance.

Metabolomics, a promising tool in non-invasive biomarkers for diagnosis, has been widely used to identify global or targeted endogenous metabolites by detecting various biosamples, such as urine and plasma (20, 21). Currently, liquid chromatography–mass spectrometry (LC-MS), nuclear magnetic resonance spectroscopy, and gas chromatography–MS are the three main analytical techniques of metabolomics and are suitable for non-targeted metabonomic mapping (22). However, LC-MS was generally employed in both metabolomic and proteomic research to identify novel biomarkers for depression, characterized by high sensitivity, high resolution, and wide coverage of metabolites and peptides (23–25). There are a few studies of plasma metabolomics in AD to screen and identify some biomarkers (26, 27). Wu et al. have found that PC (18:2(2E,4E)/0:0) and cholesterol sulfate were increased in the plasma of AD and significantly associated with AD (26). Mitro et al. (27) reported that triacylglycerol metabolites and betaine were related with the incidence of antepartum depression; C48:5 triacylglycerol and C50:6 triacylglycerol were related with higher odds of AD, whereas betaine was associated with lower percentage of AD. However, no study has yet explored changes to metabolomes in late-pregnancy women with depression symptoms.

Thus, a serum metabonomic method in the diagnosis of AD was evaluated. LC-MS–based serum metabolomic platforms were conducted to distinguish metabolic profiling of AD and non-antenatal depression (NAD). Besides, orthogonal partial least squares discriminant analysis was used to identify the differential metabolites between the two groups; Spearman’s correlation between key differential metabolites and Edinburgh Postnatal Depression Scale (EPDS), and the stepwise logistic regression analysis was used to identify potential biomarkers.

MATERIALS AND METHODS

Subject Recruitment

The protocols of this research were reviewed and approved by the Medical Ethics Committee of The Affiliated Hospital of Guizhou Medical University. All participants were asked to sign informed consent before sample collection; also, all procedures were conducted according to the principles expressed in the Declaration of Helsinki. In present study, 60 subjects were recruited from the psychiatry department of the Affiliated Hospital of Guizhou Medical University from September 2015 to September 2016. All singleton-pregnancy subjects were screened by licensed obstetricians and psychiatrists. The inclusion criteria were as follows: (1) late pregnancy (gestational weeks ≥28); (2) parity ≤4; (3) between the ages of 22 and 40 years; (4) body mass index (BMI) at prepregnancy >18.5 and <30 kg/m²; (5) complete clinical data; and (6) no history of mental or cognitive illness before pregnancy. The exclusion criteria were as follows: (1) educational level <9 years; (2) history of psychoactive substance abuse; (3) with severe systemic diseases such as metabolic encephalopathy and liver or kidney disease; and (4) complications associated with pregnancy.

The diagnosis of perinatal depression (AD) was implemented based on a renowned approach as described in the previous studies (17, 26). All subjects need to fill out the assessment scale, named EPDS, and EPDS is a self-administered instrument that includes 10 statements, scored from 0 to 3, rendering a maximum score of 30. Subjects with an EPDS-10 ≥10 were defined as AD subjects, whereas the NAD group subjects with EPDS-10 <10 (17).

Sample Collection and Preparation

The fasting blood was collected from the elbow vein of subjects in the morning using 5-mL Vacutainer tubes. Then, the blood was allowed to static 30 min at room temperature and followed by centrifugation at 3,000 revolutions/min (rpm) for 15 min. Each aliquot (150 µL) of the plasma sample was stored at −80°C until further analyses. The sample extraction protocol was based on previously published literature (28). Briefly, 50-µL sample and 150 µL of extract solution [acetoniitrile: methanol = 50:50 (vol/vol), containing isotopically-labeled internal standard mixture], were taken to an Eppendorf tube (1.5 mL), vortexed the samples for 30 s, and sonicated for 15 min. Then, these were centrifuged at 12,000 rpm for 15 min at 4°C followed by
incubation for 60 min at −40°C (29). Finally, the supernatant was collected and transferred to a new sample vial for LC-MS/MS analysis. Quality control samples were prepared by pooling the equivalent supernatants of all samples.

**LC-MS/MS Analysis**

The Vanquish™ UHPLC system (Thermo Fisher Scientific, Waltham, MA, USA) with a Waters ACQUITY UPLC BEH Amide column (2.1 × 100 mm, 1.7µm) was used to separate the metabolites, respectively. The temperature of column and autosampler was set at 25°C and 4°C, respectively, and the volume of injection was 3 µL. The mobile phase (A) was prepared by dissolving 25 mmol/L ammonium acetate and ammonia hydroxide in water and adjusted the pH of solution to 9.75, and the mobile phase (B) consisted of 100% acetonitrile. The analysis was carried out with elution gradient as follows: 0–0.5 min, 5% A; 0.5–7.0 min, 5–35% B; 7.0–8.0 min, 35–60% A; 8.0–9.0 min, 60% A; 9.0–9.1 min, 60–5% A; 9.1–12.0 min, 5% A (30).

The Q Exactive HFX mass spectrometer (Orbitrap MS, Thermo Fisher Scientific) system and MS/MS data acquisition control were performed by acquisition software (Xcalibur™ 4.0 software, Thermo). Specification of the ESI source was set as follows (30): (1) the flow rate of sheath gas and Aux gas flow rate were 50 and 10 Ar; (2) the capillary temperature was 320°C; (3) full MS resolution and MS/MS resolution of 60,000 and 7,500, respectively; (4) collision energy of 10/30/60 in NCE mode; and (5) spray voltage of 3.5 kV (positive) or −3.2 kV (negative), respectively.

**Statistical and Bioinformatics Analysis**

The raw data from metabolites were converted to the mzML format using Proteo Wizard MS control and processed with an in-house program, which was developed using R and based on XCMS, for peak detection, extraction, alignment, and integration. Internal standard normalization was employed to linearly shift the RT across the entire run for metabolite analysis (31). Then, peak annotation was processed by an in-house MS/MS database. Subsequently, the data matrix was imported into SIMCA-P V16.0.2 software (Umetrics, Umea, Sweden) for multivariable statistical analysis. Then, the orthogonal projection to latent structures−discriminant analyses (OPLS-DA) model was applied to visualize the discrimination between the AD and NAD groups in both positive and negative models. The variable importance in the projection (VIP) value was obtained from each variable in the OPLS-DA model and validation by 7-fold cross-validation and 200 permutation tests. Meanwhile, the non-parametric Mann−Whitney U test was conducted to analyze the metabolites, and multiple test corrections using the Benjamini−Hochberg correction were applied to valuate statistical significance. The metabolites with VIP values >1.0 and Q value < 0.05 were considered to be statistically significant, whereas variables that were not significantly changed were discarded (32, 33). The metabolites identified were mapped by MS/MS spectral similarities with score ≥0.8 based on an in-house database (34). In addition, the differential metabolites were mapped into their biochemical pathways through metabolic pathway enrichment and pathway analysis based on MetaboAnalyst 5.0 (http://www.metaboanalyst.ca), which uses the high-quality Kyoto Encyclopedia of Genes and Genomes metabolic pathways as the backend knowledge base (34, 35), and a pathway with $p < 0.05$ was considered to be significant (36).

All data analyses were conducted using SPSS 22.0 (IBM Corp., Armonk, NY, USA) or RStudio version 1.2.1335-2009-2019 (RStudio, Inc.) software. Data were assessed for normality of distribution using the Shapiro–Wilk test first. The two-tailed Student t test or Mann−Whitney U test was used to analyze clinical characteristics (age, BMI, gestational weeks, education level, and EPDS). Heatmap and Spearman’s rank correlation analysis of key differential metabolites were conducted using RStudio. Then, the stepwise binary logistic regression analysis and receiver operating characteristic (ROC) curve analysis were performed to explore biomarkers for distinguishing NAD from AD. The area under the curve (AUC) was used to assess the accuracy of diagnostic accuracy, such as 0.8 as excellent (<0.9 as good and 0.9 < AUC ≤ 1.0 as excellent (35)). $p < 0.05$ was considered significant.

### RESULTS

**Participant Characteristics**

The clinical and anthropometric characteristics of all the participants included in the study are summarized in Table 1. A total of 20 patients with AD and 40 with NAD were recruited for this study. There were no significant differences ($p > 0.05$) in age, BMI of pre-pregnancy and pregnancy, gestational weeks, or education level between the two groups.

**LC-MS/MS Metabolomics Analysis**

LC-MS/MS metabolomic platform was used to assess the contributions of serum metabolome. After data normalization, the OPLS-DA model revealed that the AD and NAD patients could be significantly separated with little overlap in the negative mode (R2X = 0.187, R2Y = 0.812, Q2 = 0.326, Figure 1A).
FIGURE 1 | Multivariate statistical analysis. An OPLS-DA model showed that the AD patients (red circle) could be separated from the NAD (blue square) with little overlap in the negative mode (A) and positive (B). Validation of the OPLS-DA model by the 200-time permutation test suggested that the original model was valid and not overfitted in negative mode (C) and positive (D).

FIGURE 2 | Volcano plot representing the significant variables in the discrimination between AD and NAD groups in the negative mode (A) and positive (B). The non-significant and the significant up-regulation and down-regulation variables are represented in gray, red, and blue (q < 0.05 and fold change (AD/NAD) > 1). VIP, variable importance in the projection.
TABLE 2 | Differential metabolites in the serum between the antenatal depression (AD) and antenatal depression (NAD) groups.

| Metabolites name | HMDB | Class | RT | VIP | Q   | FC | ESI |
|------------------|------|-------|----|-----|-----|----|-----|
| l-Glutamic acid  | HMDB0000148 | Amino acids | 418.1460 | 1.71 | 2.85E-03 | 0.36 | – |
| l-Phenylalanine  | HMDB0000159 | Amino acids | 277.3210 | 1.65 | 7.01E-03 | 0.65 | – |
| l-Serine         | HMDB0000187 | Amino acids | 392.1675 | 1.05 | 3.62E-03 | 0.56 | + |
| N-acetyl-l-phenylalanine | HMDB0000512 | Amino acids | 209.5230 | 1.34 | 1.23E-02 | 0.65 | – |
| Phenylacetylglycine | HMDB0000821 | Amino acids | 207.9650 | 1.28 | 1.51E-02 | 0.60 | – |
| l-Norleucine     | HMDB0001645 | Amino acids | 283.8880 | 1.21 | 1.17E-02 | 0.76 | – |
| 4-Guanidinobutanoic acid | HMDB0003464 | Amino acids | 372.8890 | 1.39 | 2.68E-02 | 1.71 | + |
| N-acetyl-l-phenylalanine | HMDB0000512 | Amino acids | 209.5230 | 1.34 | 1.23E-02 | 0.65 | – |
| Phenylacetylglycine | HMDB0000821 | Amino acids | 207.9650 | 1.28 | 1.51E-02 | 0.60 | – |
| l-Norleucine     | HMDB0001645 | Amino acids | 283.8880 | 1.21 | 1.17E-02 | 0.76 | – |
| 4-Guanidinobutanoic acid | HMDB0003464 | Amino acids | 372.8890 | 1.39 | 2.68E-02 | 1.71 | + |
| N-acetyl-l-phenylalanine | HMDB0000512 | Amino acids | 209.5230 | 1.34 | 1.23E-02 | 0.65 | – |
| Phenylacetylglycine | HMDB0000821 | Amino acids | 207.9650 | 1.28 | 1.51E-02 | 0.60 | – |
| l-Norleucine     | HMDB0001645 | Amino acids | 283.8880 | 1.21 | 1.17E-02 | 0.76 | – |
| 4-Guanidinobutanoic acid | HMDB0003464 | Amino acids | 372.8890 | 1.39 | 2.68E-02 | 1.71 | + |
| N-acetyl-l-phenylalanine | HMDB0000512 | Amino acids | 209.5230 | 1.34 | 1.23E-02 | 0.65 | – |
| Phenylacetylglycine | HMDB0000821 | Amino acids | 207.9650 | 1.28 | 1.51E-02 | 0.60 | – |
| l-Norleucine     | HMDB0001645 | Amino acids | 283.8880 | 1.21 | 1.17E-02 | 0.76 | – |
| 4-Guanidinobutanoic acid | HMDB0003464 | Amino acids | 372.8890 | 1.39 | 2.68E-02 | 1.71 | + |
| N-acetyl-l-phenylalanine | HMDB0000512 | Amino acids | 209.5230 | 1.34 | 1.23E-02 | 0.65 | – |
| Phenylacetylglycine | HMDB0000821 | Amino acids | 207.9650 | 1.28 | 1.51E-02 | 0.60 | – |

(Continued)
Table 2 (Continued)

| Metabolites name                              | HMDB       | Class     | RT       | VIP     | Q        | FC       | ESI+/- |
|----------------------------------------------|------------|-----------|----------|---------|----------|----------|--------|
| 1-Pyrroline                                  | HMDB0012497| Compounds | 330.0500 | 1.07    | 2.69E-02 | 0.87     | +      |
| Bortezomib                                   | HMDB0014334| Compounds | 287.3350 | 1.48    | 3.15E-03 | 0.25     | -      |
| Mitomycin                                    | HMDB0014450| Compounds | 189.6270 | 1.24    | 1.17E-02 | 0.56     | +      |
| Tamsulosin                                   | HMDB0014844| Compounds | 76.5542  | 1.54    | 1.75E-03 | 0.05     | +      |
| Fludarabine                                  | HMDB0015206| Compounds | 201.1370 | 1.44    | 2.28E-02 | 0.96     | +      |
| 3-Feruloyl-1,5-quinolactone                  | HMDB0029289| Compounds | 189.9265 | 1.35    | 4.78E-03 | 0.41     | +      |
| Ceanothine E                                 | HMDB0029342| Compounds | 105.3030 | 1.53    | 1.80E-03 | 0.01     | +      |
| 1-Methyl-1,3-cyclohexadiene                  | HMDB0031532| Compounds | 31.8345  | 1.10    | 1.56E-02 | 0.76     | +      |
| Acrylic acid                                 | HMDB0031647| Compounds | 72.0964  | 1.94    | 1.45E-02 | 0.65     | -      |
| 1,9-Nonanedithiol                            | HMDB0031710| Compounds | 249.6605 | 1.29    | 3.97E-02 | 1.13     | +      |
| d-2,3-Dihydroxypropanoic acid                | HMDB0031818| Compounds | 328.6070 | 1.86    | 2.92E-03 | 0.61     | -      |
| 3-(1,1-Dimethylallylscopecin 7-glucoside     | HMDB0032853| Compounds | 286.8130 | 1.41    | 1.92E-03 | 0.26     | +      |
| Honyucitrin                                  | HMDB0033536| Compounds | 286.8160 | 1.19    | 2.00E-03 | 0.32     | +      |
| Sisoriside                                   | HMDB0038932| Compounds | 287.6550 | 1.38    | 2.33E-03 | 0.06     | +      |
| 2-[3-(4-Dihydroxyphenethyl)-6-epi-elenaiate  | HMDB0039137| Compounds | 285.0410 | 1.03    | 2.47E-03 | 0.33     | +      |
| Kanzolol I                                   | HMDB0040606| Compounds | 82.8688  | 1.25    | 1.73E-03 | 0.04     | +      |
| 1-O-2'-Hydroxy-4'-methoxycaffeoyl-b-d-glucose| HMDB0040866| Compounds | 190.0090 | 1.68    | 2.66E-03 | 0.50     | +      |
| Foeniculoside VII                           | HMDB0041548| Compounds | 71.7108  | 1.15    | 1.74E-03 | 0.13     | +      |
| Sofalcone                                    | HMDB0042013| Compounds | 287.8165 | 1.39    | 1.82E-03 | 0.24     | -      |
| Acetone cyanhydrin                           | HMDB0060427| Compounds | 375.5790 | 1.50    | 2.28E-03 | 0.75     | +      |
| N-acetyl-L-muramoyl-alfa                     | HMDB0060494| Compounds | 71.9358  | 1.24    | 1.84E-03 | 0.09     | +      |
| α-Hydroxytyramoxil                           | HMDB0060585| Compounds | 424.0660 | 1.70    | 2.11E-02 | 1.94     | +      |
| Diethyl phthalic acid                        | HMDB0094660| Compounds | 69.2197  | 1.79    | 1.78E-02 | 0.07     | -      |
| Cholesterol                                  | HMDB0000067| Steroids  | 30.9224  | 1.03    | 1.58E-03 | 0.15     | +      |
| Cholesta-4,6-dien-3-one                      | HMDB0023944| Steroids  | 31.8528  | 1.49    | 1.44E-03 | 0.43     | +      |
| Tetrahydroaldosterone-3-glucuronide         | HMDB0010357| Steroids  | 96.0803  | 1.16    | 1.74E-03 | 0.02     | +      |
| Betamethasone                                | HMDB0014586| Steroids  | 77.2825  | 1.25    | 1.75E-03 | 0.06     | +      |
| Fluocinolone acetonide                       | HMDB0014729| Steroids  | 82.5630  | 1.30    | 1.79E-03 | 0.03     | +      |
| Desglucopherotinin                           | HMDB0034362| Steroids  | 433.7785 | 1.71    | 8.37E-03 | 1.76     | +      |

*Metabolites with VIP > 1.0 and Q < 0.05 were deemed statistically different. The q value column was based on non-parametric Mann–Whitney U test and Benjamini–Hochberg correction of the normalized MS data.

*The FC was calculated by the average mass response (area) ratio (FC = AD/NAD).

ESI, electrospray ionization; VIP, importance in the projection; FC, fold change; Rt, retention time.

and positive mode (R2X = 0.264, R2Y = 0.766, Q2 = 0.452, Figure 1B). Moreover, the 200-permutation test and a typical 7-fold cross-validation were performed, and the results showed that the built model was valid and not over-fitted in the negative mode (R2Y = 0.73, Q2 = −0.65, Figure 1C) and positive (R2Y = 0.60, Q2 = −0.78, Figure 1D).

**Screening of Differential Metabolites**

Significantly different metabolites were visualized as a volcano plot by plotting the -log10 q value (y axis) against the corresponding log2 fold change (AD/NAD) (x axis), and the differential metabolites were screened according to the set criteria (VIP > 1 and Q < 0.05). The volcano plot represents the significant variables in the discrimination between AD and NAD groups in the negative (Figure 2A) and positive (Figure 2B) mode. Then, all the different metabolites were identified and matched by MS/MS spectra based on an in-house database and found that 79 metabolites were significantly different between two groups (Table 2), mainly related to lipid and amino acids.

**Functional and Pathway Analysis of Differential Serum Metabolites**

All the differential metabolites were mapped into their biochemical pathways through metabolic enrichment and pathway analysis based on the database MetaboAnalyst 5.0, the overview of pathway enrichment and analysis is shown in Figures 3A,B. It revealed evident disorders in five differential metabolic pathways that emerged with pathway impact > 0 and p < 0.05 (Table 3), including glycerophospholipid metabolism (p = 0.0123) and amino acid metabolism, such as glycine, serine, and threonine metabolism (p = 0.0001) and Alanine, aspartate, and glutamate metabolism (p = 0.0334).

Then, the heatmap plotted to visualize the key differential metabolomes, which revealed that the whole metabolome
significantly changed in both groups (Figure 4A). The Spearman’s correlation was evaluated among the 15 key differential metabolites, and almost all of them are negatively correlated with depression symptom (EPDS), except that PC (16:0/16:0) \((r = 0.537, p < 0.001)\) and betaine \((r = 0.329, p = 0.010)\) were significantly positive correlated with EPDS, and L-serine \((r = 0.198, p = 0.129)\) was not (Figure 4B).

The stepwise binary logistic regression analysis of the whole differential metabolites to predicted probability and the ROC analysis to build a curve using the obtained probabilities showed that the identified simplified biomarker panel [betaine, PC (16:0/16:0) and succinic acid] could yield an AUC of 0.960 (95% confidence interval = 0.911–1.000, specificity = 95%, sensitivity = 85%) (Figure 4C). These results demonstrated that this simplified biomarker panel had an excellent diagnostic performance in discriminating AD from NAD. Finally, the molecular interactions related to amino acids and glycerophospholipid metabolism were investigated. The results showed the key metabolites were mainly mapped into the “glycerophospholipid metabolism,” “alanine, aspartate, and glutamate metabolism,” and “serine and threonine metabolism.” The majority of metabolites of these pathways were decreased in the AD group relative to the NAD group (Figure 5).

**DISCUSSION**

To our knowledge, this is the first study to use LC-MS/MS platform to evaluate serum metabolites in late-pregnancy women with and without depression symptoms. In the overall analysis, 79 metabolites were significant different between AD and NAD, which were related to amino acids and lipids (mainly about fatty acid and glycerophospholines). Specifically, we found that most of the key metabolites were related to “amino acid metabolism” including “glycine, serine, and threonine metabolism,” “alanine, aspartate and glutamate metabolism,” and

---

**TABLE 3** The top five metabolic pathways analysis via MetaboAnalyst based on all identified differential metabolites.

| No. | Pathway name                                    | Compound hits | p value  | Pathway impact | Metabolites                                                                                       |
|-----|-------------------------------------------------|---------------|----------|----------------|----------------------------------------------------------------------------------|
| 1   | Glycine, serine, and threonine metabolism       | 6/33          | 0.0001   | 0.34           | Choline, betaine, L-serine, hydroxypyruvate, 2-ketobutyric acid, d-2,3-dihydroxypropanoic acid |
| 2   | Glyoxylate and dicarboxylate metabolism         | 5/32          | 0.0011   | 0.37           | L-Serine, hydroxypyruvate, citric acid, d-2,3-dihydroxypropanoic acid              |
| 3   | Arachidonic acid metabolism                    | 4/36          | 0.0123   | 0.02           | 20-Hydroxyicosatetraenoic acid, 5-HETE, leukotriene B4, PC (16:0/16:0)             |
| 4   | Glycerophospholipid metabolism                 | 4/36          | 0.0123   | 0.19           | Choline, PC (16:0/16:0), glycerophosphocholine, Lys0PC [P-18:1(9Z)]               |
| 5   | Alanine, aspartate and glutamate metabolism    | 3/28          | 0.0334   | 0.20           | Citric acid, L-glutamic acid, succinic acid                                     |
“glycerophospholipid metabolism.” Furthermore, correlation analysis revealed that PC (16:0/16:0) and betaine were associated with higher AD risk. Finally, a potential biomarker panel consisting of three serum metabolite biomarkers [betaine, PC (16:0/16:0) and succinic acid] was identified. This panel could discriminate pregnant women with AD from those with NAD with AUC of 0.960.

Depression is a heterogeneous and multifactorial disorder, while the molecular mechanisms that underlie depression remain unclear. Recently, a growing body of evidence suggests that lipid metabolism plays a vital role in the pathophysiology of depression (22, 37–39). Lipids are a fundamental constituent of cellular and subcellular membranes and perform diverse roles in biological functions, such as regulating receptor-mediated signaling processes and transmembrane transport (40). Liu et al. have found that lysophosphatidylcholine (LysocPC), phosphatidylcholine (PC), triacylglycerol (TG), etc., remarkably increased in the plasma of depression patients and showed a significantly positive correlation with depression severity (41). PC is the most abundant phospholipid of all mammalian cell types and subcellular organelles, accounting for 40–50% of total cellular phospholipids (22, 37). LysocPC, an intermediate of PC metabolism, is produced by the cleavage of PC by phospholipase A2 (PLA2) (42), and LysocPC is converted back to PC via lysophosphatidylcholine acyltransferase (43). Then, LysocPC is orderly deacylated to glycerol–phosphocholine and choline by lysophospholipase I and glycerol–phosphocholine phosphodiesterase via glycerophospholipid metabolism pathway (44). In our study, we found that PC (16:0/16:0), choline, LysocPC [P-18:1(9Z)], and glycerol–phosphocholine are related to glycerophospholipid metabolism. PC (16:0/16:0) is up-regulated in the AD compared with those of healthy mothers during pregnancy, whereas LysocPC [P-18:1(9Z)], glycerol–phosphocholine, and choline were down-regulated. The
results may be caused by the dysfunction of PC synthesis and metabolism. PC, including PC (16:0/16:0), is primarily made in mammalian cells from choline through the CDP–choline pathway, which accounts for 95% of the total choline pool in mammalian tissue (45), and PC is also metabolized to LysoPC, glycerophospholipid, and choline via glycerophospholipid metabolism pathway (46), in line with previous findings that the levels of PC (16:0/16:0) were obviously increased in the plasma of the AD group (26) and choline and glycerol–phosphocholine were significantly decreased in the urine of patients with moderate depression (Hamilton Depression Scale score ranged from 18 to 24) (47). Masataka et al. suggested that glycerol–phosphocholine can prevent the aging-related decline in cognitive function, which plays a vital role in sustaining structural and functional integrity of cellular membranes including neuronal membranes (48). In addition, Zheng et al. have also found that the metabolites in hippocampal depressive macaques were significantly different from those of controls, which were mainly enriched in glycerophospholipid metabolism (49). Given that the changes of PC (16:0/16:0), choline, LysoPC [P-18:1(9Z)], and glycerol–phosphocholine are inconsistent, alterations of any of them would cause disturbance of glycerophospholipid metabolism. Thus, the disturbance of glycerophospholipid metabolism is associated with depression.

Depression, a serious mental illness, is influenced by genes and the environment. It has reported that the environmental factors regulated the gene expression and function of neuronal membrane via epigenetic mechanisms (50). Choline is a necessary nutrient and acts as an indirect methyl donor, which is required for normal brain growth and development (51). Choline was also a precursor of the neurotransmitter acetylcholine, PC, and betaine, involved in several critical physiological functions (52), such as modulation of gene expression, synaptic plasticity, and cholinergic signaling (50, 51). Betaine is a direct methyl donor, which can be obtained from diet or transformed from choline (53). A recent study revealed that the concentrations of choline and betaine were significantly positive and a trending positive correlation with depression scores (EPDS), respectively (54), and betaine was associated with the severity of depression of psychiatric patients, who were diagnosed with major depressive disorder (MDD) or bipolar disorder (55). Thus, the levels of choline and betaine are associated with the clinical status of depression. In the present study, the choline was an intermediate between disturbance of glycerophospholipid metabolism and glycine, serine, and threonine metabolism, and the choline is distinctly lower in AD women than the controls; betaine is observed to be increased in the AD group and involved in disturbance of glycine, serine, and threonine metabolism. In line
with previous findings, the levels of betaine increased in urine samples from subjects with bipolar disorders; choline was down-regulated in the plasma of depressed patients and reversed to the normal levels after Xiaoyaosan treatment (56). The results may explain the oxidation of choline into betaine (57). In addition, total choline and betaine significantly decreased in the AD group, compared with those from the NAD group. Both choline and betaine are involved in one-carbon metabolism, including folate and methionine cycles (58). Choline can indirectly donate its methyl groups and participate in folate-mediated one-carbon metabolism via its oxidation to betaine by choline oxidase (50), while betaine is an essential methyl donor for the methionine–homocysteine cycle. Based on the above evidence, the change in choline and betaine disturbs the one-carbon metabolism and influences the expression of pivotal genes via epigenetic mechanisms, and these genes were related to memory, learning, and cognitive functions.

Accumulating evidence supports that amino acid metabolism and glutamatergic system are involved in the pathogenesis of depression (21, 59). A vast evidence proved that the glutamatergic system can be a novel therapeutic target of MDD, particularly via N-methyl-D-aspartate receptors (NMDARs) (60), such as NMDAR antagonist ketamine (61). In this study, we found that L-glutamic acid (Glu), succinic acid, and citric acid decreased in the serum of pregnant women with depression, which was related to alanine, aspartate, and glutamate metabolism pathway. In line with previous studies, Glu decreased in the dorsolateral prefrontal cortex of individuals with depression, as well as in the anterior cingulate cortex (62). In addition, succinate and citrate are important for the tricarboxylic acid (TCA) cycle. TCA cycle is the final common oxidative pathway and most effective energy metabolism pathway. Succinate is an important intermediate of the TCA cycle, and it also interacts with the metabolism of the Glu–γ-aminobutyric acid–glutamine pathway (63). Glu also can be a substrate for the TCA cycle, as it can be converted to α-ketoglutarate by transaminases or glutamate dehydrogenase (64). It is the main excitatory neurotransmitter released by synapses in the central nervous system and regulates synaptic plasticity, cognitive processes, and reward and emotional processes (65). Therefore, Glu signaling is at the crossroad of multiple metabolic pathways and, accordingly, including the influence of TCA cycle and the “alanine, aspartate, and glutamate metabolism” pathway. The dysfunction of TCA may play a role in the pathophysiology of depression.

LIMITATIONS

Some limitations need to be addressed. First, relatively small sample size and late-pregnancy subjects were enrolled in this study; future studies with large-scale samples are still needed to validate our study. Second, all subjects were from the same location and might share the same dietary habits, which may restrict the generalization of the findings. Third, only serum metabolites were studied, and further studies should collect other biological samples from the same subjects. Fourth, the number of differential metabolites might be not enough to obtain the robust results of pathway analysis and enrichment analysis; thus, future studies are still needed to validate and support these results. Therefore, these findings shed new light to further elucidate the molecular mechanism of depression. And our preliminary investigation found that studies on potential biomarkers for AD and key metabolic pathways are needed for further validation.

CONCLUSION

In summary, 79 significant differential metabolites between AD and NAD were identified by LC-MS/MS. We also found that these metabolites mainly influenced “amino acids metabolism” and “glycerophospholipid metabolism.” Meanwhile, potential serum diagnostic metabolite panels [betaine, PC (16:0/16:0) and succinic acid] clearly discriminated AD from NAD with excellent accuracy. These findings may aid in uncovering the molecular pathogenesis of AD and then prompting the development of diagnostic and prognostic tests for the disorder.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the affiliated hospital, Guizhou Medical University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

TZ: study concept and design. TT, XG, and XZ: performed the experiments. TT: experimental technical guidance. QM: data analysis, manuscripts drafting, and revised. All authors reviewed and approved the manuscript before its submission.

FUNDING

This work was supported by the Open Project Funding of Shanghai Key Laboratory of Forensic Medicine (Academy of Forensic Science, KF1810) and Science and Technology Fund of Guizhou Province (Qian Ke He LH [2015] 7411).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.679451/full#supplementary-material
REFERENCES

1. Yin X, Sun N, Jiang N, Xu X, Gan Y, Zhang J, et al. Prevalence and associated factors of antenatal depression: systematic review and meta-analyses. Clin Psychol Rev. (2021) 83:101932. doi: 10.1016/j.cpr.2020.101932

2. Shortis E, Warrington D, Whittaker P. The efficacy of cognitive behavioral therapy for the treatment of antenatal depression: a systematic review. J Affect Disord. (2020) 272:485–95. doi: 10.1016/j.jad.2020.03.067

3. Nisar A, Yin J, Waqaas A, Bai X, Wang D, Rahaman A, et al. Prevalence of perinatal depression and its determinants in Mainland China: a systematic review and meta-analysis. J Affect Disord. (2020) 277:1022–37. doi: 10.1016/j.jad.2020.07.046

4. Mahendra R, Puthussery S, Amalan M. Prevalence of antenatal depression in South Asia: a systematic review and meta-analysis. J Epidemiol Community Health. (2019) 73:768–77. doi: 10.1136/jech-2018-211819

5. Redinger S, Pearson RM, Houle B, Norris SA, Rochat TJ. Antenatal depression and anxiety across pregnancy in urban South Africa. J Affect Disord. (2020) 277:296–305. doi: 10.1016/j.jad.2020.08.010

6. Nishi D, Su KP, Uzuda K, Chang JP, Hamazaki K, Ishima T, et al. Plasma estradiol levels and antidepressive effects of omega-3 fatty acids in pregnant women. Brain Behav Immun. (2020) 85:29–34. doi: 10.1016/j.bbi.2020.02.014

7. Sawyer KM, Zunszain PA, Pariante CM. Intergenerational transmission of depression: clinical observations and molecular mechanisms. Mol Psychiatry. (2019) 24:1157–77. doi: 10.1038/s41380-018-0265-4

8. Barch DM, Rogers C. Maternal depression and child development: clues to causal mechanisms from potential confounders. Am J Psychiatry. (1997) 154:680–2. doi: 10.1176/appi.ajp.19970707

9. Malhi GS, Mann J. Depression. Lancet. (2018) 392:2299–312. doi: 10.1016/S0140-6736(18)31948-2

10. Beurel E, Toups M, Nemeroff CB. The bidirectional relationship of depression and inflammation: double trouble. Neurotherapeutics. (2020) 17:234–56. doi: 10.1007/s11528-020-00796-z

11. Sun Y-F, Chang Q, Wu Q-J, Gao S-J, Zang S-T, Liu Y-S, et al. Association between disordered gut microbiota and changes of neurotransmitter levels and short-chain fatty acids in depressed mice. Transl Psychiatry. (2020) 10:350. doi: 10.1038/s41389-020-01038-3

12. Wu ZX, Zhao P, Long ZH, Li J, Yang GY, Zhang QL, et al. Biomarker screening for antenatal depression in women who underwent caesarean section: a matched observational study with plasma Lipidomics. BMC Psychiatry. (2019) 19:259. doi: 10.1186/s12888-019-2241-4

13. Mitro SD, Larrabure-Torrealva GT, Sanchez SE, Molsberry SA, Williams MA, Clish C, et al. Metabolic markers of antepartum depression and suicidal ideation. J Affect Disord. (2020) 262:422–8. doi: 10.1016/j.jad.2019.11.061

14. Dunn WB, Brodburnt D, Begley P, Zelenia E, Francis-Mcintyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. (2011) 6:1060–83. doi: 10.1038/nprot.2011.335

15. Xiao J, Wang D, Wang L, Jiang Y, Xue L, Sui S, et al. Increasing L-lsine production in Corynebacterium glutamicum by engineering amino acid transporters. Amino Acids. (2020) 52:1363–74. doi: 10.1007/s00726-020-02893-6

16. Wang J, Zhang T, Shen X, Liu J, Zhao D, Sun Y, et al. Serum metabolomics for early diagnosis of esophageal squamous cell carcinoma by UHPLC–QTOF/MS. Metabolomics. (2016) 12:116. doi: 10.1007/s11306-016-1050-5

17. Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. (2006) 78:779–87. doi: 10.1021/ac051437y

18. Chen L, Chang R, Pan S, Xu J, Cao Q, Su G, et al. Plasma metabolomics study of Vogt-Koyanagi-Harada disease identifies potential diagnostic biomarkers. Exp Eye Res. (2020) 196:108670. doi: 10.1016/j.expeye.2020.108670

19. Xie J, Chen C, Hou L, Zhou CJ, Fang L, Chen JF. Dual metabolic platforms identified a novel urinary metabolite signature for hepatitis B virus-infected patients with depression. Diabetes Metab Syndr Obes. (2013) 6:1677–83. doi: 10.2147/DMSO.S251034

20. Liu W, Wang Q, Chang J. Global metabolic profiling of trastuzumab resistant gastric cancer cells reveals major metabolic pathways and metabolic signatures based on UHPLC-Q exactive-MS/MS. RSC Adv. (2019) 9:41192–208. doi: 10.1039/C8RA06607A

21. Wang T, Bai S, Wang W, Chen Z, Chen J, Liang Z, et al. Diterpene Ginkgolides exert an antidepressant effect through the Nrf-3-TraK-A and Ras-MAPK pathways. Drug Des Desv Ther. (2020) 14:1279–94. doi: 10.2147/DDDT.S29145

22. Pu J, Liu Y, Zhang H, Tian L, Gui S, Yu Y, et al. An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder. Mol Psychiatry. (2020). doi: 10.1038/s41380-020-0645-4

23. Wu Y, Fu Y, Rao C, Li W, Liang Z, Zhou C, et al. Metabolic analysis reveals metabolic disturbances in the prefrontal cortex of the lipopolysaccharide-induced mouse model of depression. Behav Brain Res. (2016) 308:115–27. doi: 10.1016/j.bbr.2016.03.032

24. Li J, Zhang SX, Wang W, Cheng K, Guo H, Rao CL, et al. Potential antidepressant and resilience mechanism revealed by metabolic study on peripheral blood mononuclear cells of stress resilient rats. Brain Behav. Res. (2017) 320:12–20. doi: 10.1016/j.bbr.2016.11.035
39. Zheng P, Fang Z, Xu XJ, Liu ML, Du X, Zhang X, et al. Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells. *J Affect Disord.* (2016) 195:75–81. doi: 10.1016/j.jad.2016.02.008

40. Brunkhorst-Kanaan N, Klatt-Schreiner K, Hackel J, Schröter K, Trautmann S, Hahnefeld L, et al. Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder. *Metabolism.* (2019) 95:65–76. doi: 10.1016/j.metabol.2019.04.002

41. Liu X, Li J, Zheng P, Zhao X, Zhou C, Hu C, et al. Plasma lipidomics reveals potential lipid markers of major depressive disorder. *Anal Bioanal Chem.* (2016) 408:6497–507. doi: 10.1007/s00216-016-9768-5

42. Liu P, Zhu W, Chen C, Yan B, Zhu L, Chen X, et al. The mechanisms of lysophosphatidylcholine in the development of diseases. *Life Sci.* (2020) 247:117443. doi: 10.1016/j.lfs.2020.117443

43. Anaokar S, Kodali R, Jonik B, Renne MF, Brouwers J, Lager I, et al. The metabolite signature for aging-related phenomena in old mice. *J Biol Chem.* (2019) 294:1189–1201. doi: 10.1074/jbc.RA118.005232

44. Zhu L, Wang P, Sun YJ, Xu MY, Wu YJ. Disturbed phospholipid homeostasis in endoplasmic reticulum initiates tri-o-cresyl phosphate-induced delayed neurotoxicity. *Sci Rep.* (2016) 6:37574. doi: 10.1038/srep37574

45. Ueland MP. Choline and betaine in health and disease. *J Inherit Metab Dis.* (2011) 34:3–15. doi: 10.1054/jimd.2010.9088-4

46. Law SH, Chan ML, Marathe GK, Parveen F, Chen CH, Ke LY. An updated review of lysophosphatidylcholine metabolism in human diseases. *Int J Mol Sci.* (2019) 20:1149. doi: 10.3390/ijms20051149

47. Chen JJ, Zhou CJ, Zheng P, Zhao X, Hu C, et al. Differential urinary metabolites related with the severity of major depressive disorder. *Behav Brain Res.* (2017) 332:280–7. doi: 10.1016/j.bbr.2017.06.012

48. Narukawa M, Kamiyoshihara A, Izu H, Fujii T, Matsubara K, Misaka T. Efficacy of long-term feeding of α-Glycerophosphocholine for aging-related phenomena in old mice. *Gerontology.* (2020) 66:275–85. doi: 10.1159/000504962

49. Zheng P, Wu J, Zhang H, Perry SW, Yin B, Tan X, et al. The gut microbiome modulates gut-brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression. *Mol Psychiatry.* (2020) 24:592–64. doi: 10.1038/s41380-018-0252-9

50. Bekdash AR. Neuroproteective effects of choline and other methyl donors. *Nutrients.* (2011) 3:2995. doi: 10.3390/nu31122995

51. Blusztajn JK, Slack BE, MelloTT, NFJ. Neuroprotective actions of dietary choline. *Nutrients.* (2017) 9:815. doi: 10.3390/nu9080815

52. Wiedeman AM, Barr SJ, Green TJ, Xu Z, Innis SM, Kitts DD. Dietary choline intake: current state of knowledge across the life cycle. *Nutrients.* (2018) 10:1513. doi: 10.3390/nu10011513

53. Nutaatita M, Alijosius S, Bliznikas S, Sasyte V, Viliene V, Pockevicius A, et al. Effect of betaine, a methyl group donor, on broiler chicken growth performance, breast muscle quality characteristics, oxidative status and amino acid content. *Isal J Anim Sci.* (2020) 19:621–9. doi: 10.1080/1828051X.2020.1773949

54. van Lee L, Quah PL, Saw SM, Yap FKPG, Godfrey KM, Chong YS, et al. Maternal choline status during pregnancy, but not that of betaine, is related to antenatal mental well-being: the growing up in Singapore toward healthy outcomes cohort. *Depress Anxiety.* (2017) 34:877–87. doi: 10.1002/da.22637

55. Setoyama D, Kato TA, Hashimoto R, Kunugi H, Hattori K, Hayakawa K, et al. Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients—a multicenter pilot analysis. *PLoS ONE.* (2016) 11:e0165267–e0165267. doi: 10.1371/journal.pone.0165267

56. Liu CC, Wu YF, Feng GM, Gao XX, Zhou YZ, Hou WJ, et al. Plasma-metabolite biomarkers for the therapeutic response in depressed patients by the traditional Chinese medicine formula Xiaoyaosan: a 1(H)-NMR-based metabolomics approach. *J Affect Disord.* (2015) 185:156–63. doi: 10.1016/j.jad.2015.05.005

57. Ohnishi T, Balan S, Toyoshima M, Maekawa M, Ohba H, Watanabe A, et al. Investigation of betaine as a novel psychotherapeutic for schizophrenia. *EBioMedicine.* (2019) 45:432–46. doi: 10.1016/j.ebiom.2019.05.062

58. McFadden JW, Girard CL, Tao S, Zhou B, Bernard JK, Duplessis M, et al. Symposium review: one-carbon metabolism and methyl donor nutrition in the dairy cow. *J Dairy Sci.* (2020) 103:5668–83. doi: 10.3168/jds.2019-17319

59. Wang W, Guo H, Zhang SX, Li J, Cheng K, Bai SJ, et al. Targeted metabolomic pathway analysis and validation revealed glutamatergic disorder in the prefrontal cortex among the chronic social defeat stress mice model of depression. *J Proteome Res.* (2016) 15:3784–92. doi: 10.1021/acs.jproteome.6b00577

60. Moriguchi S, Takamiy A, Noda Y, Horita N, Wada M, Tsugawa S, et al. Glutamatergic neurometabolites in major depression disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. *Mol Psychiatry.* (2019) 24:592–64. doi: 10.1038/s41380-018-0252-9

61. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. *Nat Rev Drug Discov.* (2017) 16:472–86. doi: 10.1038/nrd.2017.16

62. Henter ID, de Sousa RT, Zarate CA Jr. Glutamatergic modulators in depression. *Harv Rev Psychiatry.* (2018) 26:360–372. doi: 10.19007/hrp.00000000000183

63. Jiang S, Yan W. Succinate in the cancer-immune cycle. *Cancer Lett.* (2017) 390:45–7. doi: 10.1016/j.canlet.2017.01.019

64. Rink C, Gnyawali S, Peterson L, Khanna S. Oxygen-inducible glutamate to metabolic fuel during acute ischemic stroke. *Antioxid Redox Signal.* (2011) 14:1777–85. doi: 10.1089/ars.2011.3930

65. Gerhard DM, Wohleb ES, DumanRS. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. *Drug Discov Today.* (2016) 21:454–64. doi: 10.1016/j.drudis.2016.01.016

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mao, Tian, Chen, Guo, Zhang and Zou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.